SUPPLEMENTAL MATERIAL
Table S1. Visit 5 attendance and vital status by prevalent disease status (venous thromboembolism [VTE], coronary heart disease [CHD], stroke, or no events), Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013.

|                      | Prevalent VTE* | Prevalent CHD* | Prevalent Stroke* | No Prevalent Events |
|----------------------|----------------|---------------|-------------------|---------------------|
|                      | Analytic Sample | Alive but did not attend Visit 5† | Dead by Visit 5† | Analytic Sample | Alive but did not attend Visit 5† | Dead by Visit 5† | Analytic Sample | Alive but did not attend Visit 5† | Dead by Visit 5† | Analytic Sample | Alive but did not attend Visit 5† | Dead by Visit 5† |
| n                    | 195            | 164           | 413              | 425              | 363             | 1,431               | 208          | 270             | 746               | 5,409            | 3,530            | 3,178               |
| Age at visit 1, years| 52.8 (5.1)     | 56.0 (5.7)    | 56.5 (5.7)       | 53.4 (5.3)       | 54.8 (5.5)      | 57.1 (5.3)          | 53.4 (5.6)   | 54.9 (5.6)   | 57.3 (5.2)       | 51.8 (5.1)       | 53.7 (5.6)       | 56.7 (5.5)          |
| Age at visit 5, years‡| 76.6 (5.2)     | 79.9 (5.8)    | 73.0 (7.7)       | 77.2 (5.4)       | 78.6 (5.5)      | 71.5 (7.9)          | 77.2 (5.7)   | 78.7 (5.6)   | 72.4 (7.7)       | 75.5 (5.2)       | 77.4 (5.7)       | 71.1 (8.3)          |
| Sex, %               |                |               |                  |                  |                |                     |              |                |                  |                  |                |                     |
| Female               | 59.5           | 62.8          | 51.8             | 39.1             | 44.1           | 38.2               | 49.0         | 55.2           | 49.9              | 60.5             | 64.2           | 47.4                 |
| Male                 | 40.5           | 37.2          | 48.2             | 60.9             | 55.9           | 61.8               | 51.0         | 44.8           | 50.1              | 39.5             | 35.8           | 52.6                 |
| Race, %              |                |               |                  |                  |                |                     |              |                |                  |                  |                |                     |
| Asian                | 0              | 0.6           | 0                | 0                | 0.5            | 0                  | 0            | 0.4            | 0.1              | 0                | 0.7            | 0.1                  |
| African American     | 31.3           | 35.4          | 38.0             | 22.4             | 23.7           | 32.3               | 33.7         | 38.5           | 42.9              | 22.5             | 25.7           | 30.2                  |
| Indian               | 0              | 0             | 0                | 0                | 0.3            | 0.1                | 0            | 0              | 0                 | 0                | 0.2            | 0.2                  |
| White                | 68.7           | 64.0          | 62.0             | 77.6             | 75.5           | 67.6               | 66.3         | 61.1           | 57.0              | 77.5             | 73.4           | 69.5                  |
| BMI, kg/m²           | 29.5 (5.4)     | 30.0 (6.0)    | 29.5 (6.0)       | 27.8 (4.7)       | 28.1 (5.1)     | 29.2 (5.7)          | 27.6 (4.6)   | 28.9 (5.3)   | 28.8 (5.7)       | 27.0 (4.8)       | 27.7 (5.5)     | 27.8 (5.8)            |
| Smoking status, %    |                |               |                  |                  |                |                     |              |                |                  |                  |                |                     |
| Current              | 10.8           | 16.5          | 33.2             | 27.5             | 30.0           | 37.5               | 23.6         | 32.6           | 36.2              | 17.2             | 22.8           | 38.3                  |
| Former               | 38.5           | 33.5          | 32.7             | 37.2             | 33.1           | 34.2               | 35.1         | 24.8           | 27.8              | 32.7             | 30.7           | 31.6                  |
| Never                | 50.8           | 50.0          | 34.1             | 35.3             | 36.9           | 28.2               | 41.3         | 42.6           | 35.9              | 50.0             | 46.4           | 30.0                  |
| Unknown              | 0              | 0             | 0                | 0                | 0              | 0                  | 0            | 0              | 0                 | 0.1              | 0.1            | 0.1                   |
| Diabetes, %          | 9.2            | 11.0          | 16.2             | 12.7             | 15.4           | 32.0               | 12.0         | 15.6           | 31.0              | 4.9              | 8.0           | 16.4                 |
| Hypertension, %      | 37.4           | 43.9          | 47.7             | 32.2             | 45.2           | 58.9               | 40.4         | 50.0           | 63.0              | 22.7             | 31.5           | 41.3                  |

BMI, smoking status, diabetes and hypertension are from visit 1 only.

BMI: Body mass index

* Prevalent VTE, CHD, and stroke events are not mutually exclusive.

† Censoring date for those who did not attend visit 5: May 4, 2012 (median date of visit 5).

‡ Age at visit 5 indicates the age at death for those dead by visit 5 and age at the median visit 5 date for those who are alive but did not attend visit 5.
### Table S2. Linear regression of prevalent venous thromboembolism (VTE) with overall and gait speed scores on the Short Physical Performance Battery, Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013 and 2016 to 2017.

| Model 1 | Prevalent VTE versus No Prevalent Events | Prevalent VTE versus Prevalent CHD* | Prevalent VTE versus Prevalent Stroke* |
|---------|----------------------------------------|-------------------------------------|----------------------------------------|
|         | n                                      | Coefficient (95% CI) | p-value      | n                                      | Coefficient (95% CI) | p-value      | n                                      | Coefficient (95% CI) | p-value      |
|         |                                         |                        |              |                                         |                        |              |                                         |                        |              |
| Short physical performance battery (SPPB) score |                                         |                        |              |                                         |                        |              |                                         |                        |              |
| Model 1 | Prevalent VTE                           | 173                    | -1.47 (-1.80, -1.14) | <0.0001 | 154                     | -0.60 (-1.16, -0.04) | 0.04          | 158                     | 0.56 (-0.11, 1.23) | 0.10         |
|         | Comparison                              | 5,018                  | (Reference)    |                        | 353                     | (Reference)       |                        | 162                     | (Reference)       |
| Model 2 | Prevalent VTE                           | 173                    | -1.29 (-1.62, -0.97) | <0.0001 | 154                     | -0.97 (-1.57, -0.38) | 0.002         | 158                     | 0.53 (-0.17, 1.23) | 0.14         |
|         | Comparison                              | 5,018                  | (Reference)    |                        | 353                     | (Reference)       |                        | 162                     | (Reference)       |
| Gait speed - 4m walk (SPPB score 0-4) |                                         |                        |              |                                         |                        |              |                                         |                        |              |
| Model 1 | Prevalent VTE                           | 172                    | -0.37 (-0.46, -0.27) | <0.0001 | 153                     | -0.13 (-0.31, 0.05) | 0.16          | 157                     | 0.25 (0.04, 0.46) | 0.02         |
|         | Comparison                              | 4,988                  | (Reference)    |                        | 352                     | (Reference)       |                        | 162                     | (Reference)       |
| Model 2 | Prevalent VTE                           | 172                    | -0.32 (-0.42, -0.22) | <0.0001 | 153                     | -0.24 (-0.44, -0.05) | 0.01          | 157                     | 0.23 (0.01, 0.45) | 0.04         |
|         | Comparison                              | 4,988                  | (Reference)    |                        | 352                     | (Reference)       |                        | 162                     | (Reference)       |

**Model 1:** Linear regression adjusted for age, race-center, sex, and body mass index.

**Model 2:** Model 1 + additional adjustment for chronic obstructive pulmonary disease, diabetes, hypertensive medication, smoking status, systolic blood pressure, prevalent heart failure, and prevalent peripheral artery disease.

The linear regression coefficient represents the difference between prevalent VTE and the comparison group of each physical function and quality of life outcome.

CI: confidence interval

* Prevalent VTE, CHD, and stroke events are mutually exclusive.
Table S3. Linear regression of prevalent unprovoked venous thromboembolism (VTE) with physical function and quality of life outcomes, Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013 and 2016 to 2017.

| Quality of life - mental score | Prevalent Unprovoked VTE versus No Prevalent Events | Prevalent Unprovoked VTE versus Prevalent CHD* | Prevalent Unprovoked VTE versus Prevalent Stroke* |
|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value |
| Model 1 Unprovoked VTE | 98 | 0.03 (-1.47, 1.53) | 0.97 | 86 | -0.24 (-2.24, 1.75) | 0.81 | 92 | -0.09 (-2.35, 2.17) | 0.94 |
| Comparison | 5,295 | (Reference) | | 384 | (Reference) | | 180 | (Reference) | |
| Model 2 Unprovoked VTE | 98 | 0.32 (-1.18, 1.81) | 0.68 | 86 | 0.17 (-1.98, 2.33) | 0.88 | 92 | 0.05 (-2.34, 2.44) | 0.97 |
| Comparison | 5,295 | (Reference) | | 384 | (Reference) | | 180 | (Reference) | |

| Quality of life - physical score | Prevalent Unprovoked VTE versus No Prevalent Events | Prevalent Unprovoked VTE versus Prevalent CHD* | Prevalent Unprovoked VTE versus Prevalent Stroke* |
|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value |
| Model 1 Unprovoked VTE | 98 | -4.61 (-6.51, -2.72) | <0.0001 | 86 | -0.93 (-3.63, 1.78) | 0.50 | 92 | 0.96 (-1.76, 3.68) | 0.49 |
| Comparison | 5,295 | (Reference) | | 384 | (Reference) | | 180 | (Reference) | |
| Model 2 Unprovoked VTE | 98 | -3.59 (-5.39, -1.78) | <0.0001 | 86 | -2.93 (-5.60, -0.26) | 0.03 | 92 | -0.24 (-2.98, 2.50) | 0.86 |
| Comparison | 5,295 | (Reference) | | 384 | (Reference) | | 180 | (Reference) | |

| Short physical performance battery (SPPB) score | Prevalent Unprovoked VTE versus No Prevalent Events | Prevalent Unprovoked VTE versus Prevalent CHD* | Prevalent Unprovoked VTE versus Prevalent Stroke* |
|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value |
| Model 1 Unprovoked VTE | 90 | -1.36 (-1.81, -0.91) | <0.0001 | 81 | -0.41 (-1.09, 0.27) | 0.24 | 84 | 0.44 (-0.39, 1.26) | 0.30 |
| Comparison | 5,018 | (Reference) | | 353 | (Reference) | | 162 | (Reference) | |
| Model 2 Unprovoked VTE | 90 | -1.22 (-1.67, -0.78) | <0.0001 | 81 | -0.88 (-1.60, -0.15) | 0.02 | 84 | 0.38 (-0.49, 1.24) | 0.39 |
| Comparison | 5,018 | (Reference) | | 353 | (Reference) | | 162 | (Reference) | |

| Gait speed - 4m walk, m/s | Prevalent Unprovoked VTE versus No Prevalent Events | Prevalent Unprovoked VTE versus Prevalent CHD* | Prevalent Unprovoked VTE versus Prevalent Stroke* |
|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value |
| Model 1 Unprovoked VTE | 89 | -0.07 (-0.11, -0.03) | 0.001 | 80 | 0.0001 (-0.05, 0.05) | 0.99 | 83 | 0.06 (-0.001, 0.12) | 0.05 |
| Comparison | 4,981 | (Reference) | | 347 | (Reference) | | 159 | (Reference) | |
| Model 2 Unprovoked VTE | 89 | -0.06 (-0.10, -0.02) | 0.003 | 80 | -0.02 (-0.07, 0.03) | 0.45 | 83 | 0.05 (-0.01, 0.11) | 0.09 |
| Comparison | 4,981 | (Reference) | | 347 | (Reference) | | 159 | (Reference) | |

| Gait speed - 4m walk (SPPB score 0-4) | Prevalent Unprovoked VTE versus No Prevalent Events | Prevalent Unprovoked VTE versus Prevalent CHD* | Prevalent Unprovoked VTE versus Prevalent Stroke* |
|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value |
| Model 1 Unprovoked VTE | 89 | -0.22 (-0.35, -0.08) | 0.002 | 80 | 0.01 (-0.21, 0.22) | 0.94 | 83 | 0.30 (0.04, 0.56) | 0.02 |
| Comparison | 4,988 | (Reference) | | 352 | (Reference) | | 162 | (Reference) | |
| Model 2 Unprovoked VTE | 89 | -0.18 (-0.32, -0.05) | 0.01 | 80 | -0.12 (-0.34, 0.11) | 0.32 | 83 | 0.26 (-0.01, 0.54) | 0.06 |
| Comparison | 4,988 | (Reference) | | 352 | (Reference) | | 162 | (Reference) | |
Endurance, feet†

| Model  | Unprovoked VTE |   |   |   | Comparison |
|--------|----------------|---|---|---|------------|
| Model 1| Unprovoked VTE | 48| -32.31 (-54.67, -9.95) | 0.005 | 44 | 5.00 (-25.08, 35.08) | 0.74 | 47 | 29.81 (-2.56, 62.18) | 0.07 |
|        | Comparison     | 2,528 | 172 |   | 172 | (Reference) |   | 85 |   |   |
| Model 2| Unprovoked VTE | 48| -31.06 (-52.83, -9.29) | 0.01 | 44 | -2.90 (-34.94, 29.15) | 0.86 | 47 | 11.65 (-22.80, 46.10) | 0.50 |
|        | Comparison     | 2,528 | (Reference) |   | 172 | (Reference) |   | 85 | (Reference) |   |

Model 1: Linear regression adjusted for age, race-center, sex, and body mass index.

Model 2: Model 1 + additional adjustment for chronic obstructive pulmonary disease, diabetes, hypertensive medication, smoking status, systolic blood pressure, prevalent heart failure at visit 5, and prevalent peripheral artery disease at visit 5.

The linear regression coefficient represents the difference between prevalent unprovoked VTE and the comparison group of each physical function and quality of life outcome.

CI: confidence interval

* Prevalent unprovoked VTE, CHD, and stroke events are mutually exclusive.

† From visit #6. The linear regression models include the same covariates from visit #6 except for chronic obstructive pulmonary disease, which is from visit #5.
Table S4. Polytomous logistic regression of prevalent unprovoked venous thromboembolism (VTE) with physical function and quality of life outcomes, Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013.

| Frailty       | Prevalent Unprovoked VTE versus No Prevalent Events | Prevalent Unprovoked VTE versus Prevalent CHD* | Prevalent Unprovoked VTE versus Prevalent Stroke* |
|---------------|----------------------------------------------------|-----------------------------------------------|---------------------------------------------------|
|               | n  | VTE n | OR (95% CI)   | p-value  | n  | VTE n | OR (95% CI)   | p-value  | n  | VTE n | OR (95% CI)   | p-value  |
| Frail Model 1 |    |       |               |          |    |       |               |          |    |       |               |          |
|               | 297 | 12    | 3.70 (1.77-7.71) | 0.001    | 49  | 12    | 1.38 (0.57-3.29) | 0.47     | 30  | 10    | **            |          |
| Pre-frail     | 2,354 | 51    | 2.05 (1.24-3.38) | 0.005    | 231 | 43    | 1.20 (0.67-2.16) | 0.54     | 137 | 47    | **            |          |
| Not frail     | 2,382 | 24    | 1 (Reference)   |          | 145 | 23    | 1 (Reference)   |          | 70  | 24    | 1 (Reference) |          |
| Frail Model 2 |    |       |               |          |    |       |               |          |    |       |               |          |
|               | 297 | 12    | 3.11 (1.46-6.64) | 0.003    | 49  | 12    | **            |          | 30  | 10    | **            |          |
| Pre-frail     | 2,354 | 51    | 2.02 (1.22-3.36) | 0.007    | 231 | 43    | **            |          | 137 | 47    | **            |          |
| Not frail     | 2,382 | 24    | 1 (Reference)   |          | 145 | 23    | 1 (Reference)   |          | 70  | 24    | 1 (Reference) |          |

| Short physical performance battery (SPPB) score groups | Model 1 | Prevalent Unprovoked VTE versus No Prevalent Events | Prevalent Unprovoked VTE versus Prevalent CHD* | Prevalent Unprovoked VTE versus Prevalent Stroke* |
|--------------------------------------------------------|---------|----------------------------------------------------|-----------------------------------------------|---------------------------------------------------|
|                                                       | n  | VTE n | OR (95% CI)   | p-value  | n  | VTE n | OR (95% CI)   | p-value  | n  | VTE n | OR (95% CI)   | p-value  |
| Low (0-6) Model 1                                      | 641 | 32    | 3.83 (2.20-6.67) | <0.0001  | 104 | 28    | 1.28 (0.66-2.47) | 0.47     | 87  | 28    | 0.60 (0.30-1.22) | 0.16     |
| Fair (7-9) Model 1                                     | 1,514 | 23 | 1.23 (0.71-2.14) | 0.45     | 134 | 21    | 0.77 (0.41-1.45) | 0.42     | 74  | 23    | 0.67 (0.34-1.34) | 0.26     |
| Good (10-12) Model 1                                   | 2,953 | 35 | 1 (Reference)   |          | 196 | 32    | 1 (Reference)   |          | 85  | 33    | 1 (Reference)   |          |
| Low (0-6) Model 2                                      | 641 | 32    | 3.39 (1.91-6.02) | <0.0001  | 104 | 28    | **            |          | 87  | 28    | **            |          |
| Fair (7-9) Model 2                                     | 1,514 | 23 | 1.19 (0.69-2.07) | 0.54     | 134 | 21    | **            |          | 74  | 23    | **            |          |
| Good (10-12) Model 2                                   | 2,953 | 35 | 1 (Reference)   |          | 196 | 32    | 1 (Reference)   |          | 85  | 33    | 1 (Reference)   |          |

**Model 1**: Multinominal logistic regression adjusted for age, race-center, sex, and body mass index.

**Model 2**: Model 1 + additional adjustment for chronic obstructive pulmonary disease, diabetes, hypertensive medication, smoking status, systolic blood pressure, prevalent heart failure at visit 5 and prevalent peripheral artery disease at visit 5.

The odds ratios are comparing those with prevalent unprovoked VTE to the comparison group within each physical function and quality of life outcome group.

OR: odds ratio; CI: confidence interval

* Prevalent unprovoked VTE, CHD, and stroke events are mutually exclusive.

** Model failed to converge due to the small sample size and some covariates lacking individuals within their categories.
Table S5. Linear regression of prevalent pulmonary embolism (PE) with physical function and quality of life outcomes, Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013 and 2016 to 2017.

|                      | Prevalent PE versus No Prevalent Events | Prevalent PE versus Prevalent CHD* | Prevalent PE versus Prevalent Stroke* |
|----------------------|----------------------------------------|------------------------------------|--------------------------------------|
|                      | n          | Coefficient (95% CI) | p-value   | n          | Coefficient (95% CI) | p-value   | n          | Coefficient (95% CI) | p-value   |
| Quality of life - mental score |            |                       |           |            |                       |           |            |                       |           |
| Model 1              | Prevalent PE | 106                  | 0.96 (-0.48, 2.41) | 0.19      | 93        | 0.80 (-1.16, 2.76) | 0.42      | 95        | 0.55 (-1.70, 2.80) | 0.63      |
|                      | Comparison  | 5,295                | (Reference)   |           | 384      | (Reference)   |           | 180      | (Reference)   |           |
| Model 2              | Prevalent PE | 106                  | 1.38 (-0.06, 2.82) | 0.06      | 93        | 1.11 (-1.01, 3.23) | 0.30      | 95        | 0.65 (-1.69, 3.00) | 0.58      |
|                      | Comparison  | 5,295                | (Reference)   |           | 384      | (Reference)   |           | 180      | (Reference)   |           |
| Quality of life - physical score |            |                       |           |            |                       |           |            |                       |           |
| Model 1              | Prevalent PE | 106                  | -4.98 (-6.80, -3.16) | <0.0001   | 93        | -1.08 (-3.73, 1.57) | 0.42      | 95        | 1.20 (-1.50, 3.90) | 0.38      |
|                      | Comparison  | 5,295                | (Reference)   |           | 384      | (Reference)   |           | 180      | (Reference)   |           |
| Model 2              | Prevalent PE | 106                  | -3.59 (-5.33, -1.85) | <0.0001   | 93        | -2.95 (-5.57, -0.33) | 0.03      | 95        | 0.53 (-2.14, 3.21) | 0.70      |
|                      | Comparison  | 5,295                | (Reference)   |           | 384      | (Reference)   |           | 180      | (Reference)   |           |
| Short physical performance battery (SPPB) score |            |                       |           |            |                       |           |            |                       |           |
| Model 1              | Prevalent PE | 97                   | -1.67 (-2.11, -1.24) | <0.0001   | 88        | -0.70 (-1.38, -0.03) | 0.04      | 87        | 0.37 (-0.45, 1.19) | 0.37      |
|                      | Comparison  | 5,018                | (Reference)   |           | 353      | (Reference)   |           | 162      | (Reference)   |           |
| Model 2              | Prevalent PE | 97                   | -1.48 (-1.90, -1.05) | <0.0001   | 88        | -1.14 (-1.85, -0.42) | 0.002     | 87        | 0.33 (-0.52, 1.19) | 0.44      |
|                      | Comparison  | 5,018                | (Reference)   |           | 353      | (Reference)   |           | 162      | (Reference)   |           |
| Gait speed - 4m walk, m/s |            |                       |           |            |                       |           |            |                       |           |
| Model 1              | Prevalent PE | 92                   | -0.07 (-0.11, -0.03) | 0.001     | 83        | -0.001 (-0.05, 0.05) | 0.97      | 84        | 0.07 (0.01, 0.13) | 0.02      |
|                      | Comparison  | 4,981                | (Reference)   |           | 347      | (Reference)   |           | 159      | (Reference)   |           |
| Model 2              | Prevalent PE | 92                   | -0.05 (-0.09, -0.02) | 0.01      | 83        | -0.02 (-0.07, 0.04) | 0.50      | 84        | 0.07 (0.01, 0.13) | 0.02      |
|                      | Comparison  | 4,981                | (Reference)   |           | 347      | (Reference)   |           | 159      | (Reference)   |           |
| Gait speed - 4m walk (SPPB score 0-4) |            |                       |           |            |                       |           |            |                       |           |
| Model 1              | Prevalent PE | 96                   | -0.42 (-0.55, -0.29) | <0.0001   | 87        | -0.18 (-0.41, 0.04) | 0.10      | 86        | 0.20 (-0.06, 0.47) | 0.13      |
|                      | Comparison  | 4,988                | (Reference)   |           | 352      | (Reference)   |           | 162      | (Reference)   |           |
| Model 2              | Prevalent PE | 96                   | -0.37 (-0.50, -0.24) | <0.0001   | 87        | -0.30 (-0.54, -0.07) | 0.01      | 86        | 0.18 (-0.10, 0.46) | 0.20      |
|                      | Comparison  | 4,988                | (Reference)   |           | 352      | (Reference)   |           | 162      | (Reference)   |           |
### Endurance, feet†

| Model | Prevalent PE | Comparison | Prevalent PE | Comparison | Prevalent PE | Comparison |
|-------|--------------|------------|--------------|------------|--------------|------------|
| Model 1 | 56 -18.53 (-39.26, 2.20) 0.08 | 50 17.92 (-10.73, 46.57) 0.22 | 52 35.39 (4.30, 66.47) 0.03 |
| Model 2 | 56 -13.63 (-33.84, 6.58) 0.19 | 50 13.88 (-16.03, 43.80) 0.36 | 52 24.58 (-7.06, 56.23) 0.13 |

**Model 1**: Linear regression adjusted for age, race-center, sex, and body mass index.

**Model 2**: Model 1 + additional adjustment for chronic obstructive pulmonary disease, diabetes, hypertensive medication, smoking status, systolic blood pressure, prevalent heart failure at visit 5, and prevalent peripheral artery disease at visit 5.

The linear regression coefficient represents the difference between prevalent PE and the comparison group of each physical function and quality of life outcome.

CI: confidence interval

* Prevalent PE, CHD, and stroke events are mutually exclusive.

† From visit #6. The linear regression models include the same covariates from visit #6 except for chronic obstructive pulmonary disease, which is from visit #5.
Table S6. Polytomous logistic regression of prevalent pulmonary embolism (PE) with physical function and quality of life outcomes, Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013.

| Frailty        | Prevalent PE versus No Prevalent Events | Prevalent PE versus Prevalent CHD* | Prevalent PE versus Prevalent Stroke* |
|----------------|----------------------------------------|-----------------------------------|--------------------------------------|
|                | n          | PE n | OR (95% CI) | p-value  | n          | PE n | OR (95% CI) | p-value  | n          | PE n | OR (95% CI) | p-value |
| Frail          | 299        | 14   | 3.99 (1.97-8.09) | 0.0001 | 49         | 12   | 1.50 (0.62-3.66) | 0.37    | 31         | 11   | **          |         |
| Pre-frail      | 2,360      | 57   | 2.26 (1.37-3.72) | 0.002 | 241        | 53   | 1.51 (0.83-2.74) | 0.18    | 142        | 52   | **          |         |
| Not frail      | 2,381      | 23   | 1 (Reference) |         | 142        | 20   | 1 (Reference) |         | 68         | 22   | 1 (Reference) |         |
| Model 2        | Frail      | 299  | 14 | 3.01 (1.45-6.27) | 0.003 | 49         | 12   | **          |         | 31         | 11   | **          |         |
| Pre-frail      | 2,360      | 57   | 2.15 (1.29-3.56) | 0.003 | 241        | 53   | **          |         | 142        | 52   | **          |         |
| Not frail      | 2,381      | 23   | 1 (Reference) |         | 142        | 20   | 1 (Reference) |         | 68         | 22   | 1 (Reference) |         |
| Short physical performance battery (SPPB) groups | | | | | | | | | | | |
| Model 1        | Low (0-6)  | 647  | 38 | 4.60 (2.65-7.97) | <0.0001 | 110         | 34   | 1.52 (0.78-2.93) | 0.22    | 90         | 31   | 0.60 (0.29-1.24) | 0.17 |
| Fair (7-9)     | 1,518      | 27   | 1.50 (0.87-2.56) | 0.14  | 138        | 25   | 0.91 (0.48-1.71) | 0.77    | 77         | 26   | 0.73 (0.36-1.47) | 0.37 |
| Good (10-12)   | 2,950      | 32   | 1 (Reference) |         | 193        | 29   | 1 (Reference) |         | 82         | 30   | 1 (Reference) |         |
| Model 2        | Low (0-6)  | 647  | 38 | 3.90 (2.22-6.86) | <0.0001 | 110         | 34   | **          |         | 90         | 31   | **          |         |
| Fair (7-9)     | 1,518      | 27   | 1.41 (0.82-2.42) | 0.21  | 138        | 25   | **          |         | 77         | 26   | **          |         |
| Good (10-12)   | 2,950      | 32   | 1 (Reference) |         | 193        | 29   | 1 (Reference) |         | 82         | 30   | 1 (Reference) |         |

**Model 1**: Polytomous logistic regression adjusted for age, race-center, sex, and body mass index.

**Model 2**: Model 1 + additional adjustment for chronic obstructive pulmonary disease, diabetes, hypertensive medication, smoking status, systolic blood pressure, prevalent heart failure at visit 5 and prevalent peripheral artery disease at visit 5.

The odds ratios are comparing those with prevalent PE to the comparison group within each physical function and quality of life outcome group.

OR: odds ratio; CI: confidence interval

* Prevalent PE, CHD, and stroke events are mutually exclusive.

** Model failed to converge due to the small sample size and some covariates lacking individuals within their categories.
Table S7. Linear regression of prevalent deep-vein thrombosis (DVT) with physical function and quality of life outcomes, Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013 and 2016 to 2017.

|                      | Prevalent DVT versus No Prevalent Events | Prevalent DVT versus Prevalent CHD* | Prevalent DVT versus Prevalent Stroke* |
|----------------------|------------------------------------------|-------------------------------------|----------------------------------------|
|                      | n     | Coefficient (95% CI) | p-value       | n     | Coefficient (95% CI) | p-value     | n     | Coefficient (95% CI) | p-value     |
| Quality of life - mental score |                   |                                |               |                   |                                |               |                   |                                |               |
| Model 1 Prevalent DVT | 84    | -1.50 (-3.12, 0.12)  | 0.07          | 73    | -1.58 (-3.75, 0.59)  | 0.15         | 80    | -1.03 (-3.46, 1.41)  | 0.41         |
| Comparison           | 5,295 | (Reference)         |               | 384   | (Reference)         |               | 180   | (Reference)         |               |
| Model 2 Prevalent DVT | 84    | -1.23 (-2.84, 0.39)  | 0.14          | 73    | -0.93 (-3.24, 1.38)  | 0.43         | 80    | -0.56 (-3.13, 2.00)  | 0.67         |
| Comparison           | 5,295 | (Reference)         |               | 384   | (Reference)         |               | 180   | (Reference)         |               |
| Quality of life - physical score |                   |                                |               |                   |                                |               |                   |                                |               |
| Model 1 Prevalent DVT | 84    | -4.01 (-6.05, -1.96) | 0.001         | 73    | 0.68 (-2.21, 3.57)  | 0.64         | 80    | 1.28 (-1.67, 4.23)  | 0.39         |
| Comparison           | 5,295 | (Reference)         |               | 384   | (Reference)         |               | 180   | (Reference)         |               |
| Model 2 Prevalent DVT | 84    | -2.80 (-4.76, -0.85) | 0.005         | 73    | -0.52 (-3.37, 2.34)  | 0.72         | 80    | 0.67 (-2.31, 3.64)  | 0.66         |
| Comparison           | 5,295 | (Reference)         |               | 384   | (Reference)         |               | 180   | (Reference)         |               |
| Short physical performance battery (SPPB) score |                   |                                |               |                   |                                |               |                   |                                |               |
| Model 1 Prevalent DVT | 76    | -1.22 (-1.71, -0.73) | <0.0001       | 66    | -0.42 (-1.17, 0.33)  | 0.27         | 71    | 0.77 (-0.11, 1.65)  | 0.09         |
| Comparison           | 5,018 | (Reference)         |               | 353   | (Reference)         |               | 162   | (Reference)         |               |
| Model 2 Prevalent DVT | 76    | -1.06 (-1.54, -0.58) | <0.0001       | 66    | -0.80 (-1.58, -0.01) | 0.05         | 71    | 0.69 (-0.24, 1.62)  | 0.15         |
| Comparison           | 5,018 | (Reference)         |               | 353   | (Reference)         |               | 162   | (Reference)         |               |
| Gait speed - 4m walk, m/s |                   |                                |               |                   |                                |               |                   |                                |               |
| Model 1 Prevalent DVT | 74    | -0.08 (-0.12, -0.04) | 0.0003        | 64    | -0.001 (-0.06, 0.05) | 0.98         | 70    | 0.05 (-0.01, 0.12)  | 0.08         |
| Comparison           | 4,981 | (Reference)         |               | 347   | (Reference)         |               | 159   | (Reference)         |               |
| Model 2 Prevalent DVT | 74    | -0.07 (-0.11, -0.03) | 0.001         | 64    | -0.02 (-0.08, 0.03)  | 0.43         | 70    | 0.05 (-0.02, 0.11)  | 0.15         |
| Comparison           | 4,981 | (Reference)         |               | 347   | (Reference)         |               | 159   | (Reference)         |               |
| Gait speed - 4m walk (SPPB score 0-4) |                   |                                |               |                   |                                |               |                   |                                |               |
| Model 1 Prevalent DVT | 76    | -0.30 (-0.44, -0.15) | <0.0001       | 66    | -0.05 (-0.29, 0.19)  | 0.68         | 71    | 0.30 (0.02, 0.58)  | 0.04         |
| Comparison           | 4,988 | (Reference)         |               | 352   | (Reference)         |               | 162   | (Reference)         |               |
| Model 2 Prevalent DVT | 76    | -0.26 (-0.41, -0.12) | 0.0004        | 66    | -0.16 (-0.41, 0.09)  | 0.21         | 71    | 0.28 (-0.02, 0.57)  | 0.07         |
| Comparison           | 4,988 | (Reference)         |               | 352   | (Reference)         |               | 162   | (Reference)         |               |
| Endurance, feet† | Model 1 Prevalent DVT | 30  | -20.44 (-48.52, 7.64) | 0.15 | 28  | 13.51 (-21.46, 48.49) | 0.45 | 30  | 39.98 (4.26, 75.69) | 0.03 |
|------------------|-----------------------|-----|----------------------|------|-----|----------------------|------|-----|-------------------|------|
| Comparison       | 2,528 (Reference)     | 172 | (Reference)          | 85   | (Reference)          |
| Model 2 Prevalent DVT | 30  | -17.31 (-44.64, 10.02) | 0.21 | 28  | 13.24 (-24.20, 50.68) | 0.49 | 30  | 20.93 (-17.80, 59.65) | 0.29 |
| Comparison       | 2,528 (Reference)     | 172 | (Reference)          | 85   | (Reference)          |

**Model 1**: Linear regression adjusted for age, race-center, sex, and body mass index.

**Model 2**: Model 1 + additional adjustment for chronic obstructive pulmonary disease, diabetes, hypertensive medication, smoking status, systolic blood pressure, prevalent heart failure at visit 5, and prevalent peripheral artery disease at visit 5.

The linear regression coefficient represents the difference between prevalent DVT and the comparison group of each physical function and quality of life outcome.

CI: confidence interval

* Prevalent DVT, CHD, and stroke events are mutually exclusive.

† From visit #6. The linear regression models include the same covariates from visit #6 except for chronic obstructive pulmonary disease, which is from visit #5.
Table S8. Polytomous logistic regression of prevalent deep-vein thrombosis (DVT) with physical function and quality of life outcomes, Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013.

| Frailty                  | Prevalent DVT versus No Prevalent Events | Prevalent DVT versus Prevalent CHD* | Prevalent DVT versus Prevalent Stroke* |
|--------------------------|-----------------------------------------|-------------------------------------|----------------------------------------|
|                          | n | DVT | OR (95% CI) | p-value | n | DVT | OR (95% CI) | p-value | n | DVT | OR (95% CI) | p-value |
| Frail Model 1            |   |     |             |         |   |     |             |         |   |     |             |         |
| Frail                   | 296 | 11 | 3.67 (1.71-7.88) | 0.001   | 47 | 10 | 1.19 (0.47-3.04) | 0.72 | 29 | 9  | 0.60 (0.21-1.70) | 0.34 |
| Pre-frail               | 2,343 | 40 | 1.70 (1.00-2.91) | 0.05    | 221 | 33 | 1.02 (0.54-1.93) | 0.95 | 128 | 38 | 0.81 (0.41-1.59) | 0.53 |
| Not frail               | 2,380 | 22 | 1 (Reference) |         | 142 | 20 | 1 (Reference) |         | 68 | 22 | 1 (Reference) |         |
| Frail Model 2            |   |     |             |         |   |     |             |         |   |     |             |         |
| Frail                   | 296 | 11 | 3.30 (1.51-7.21) | 0.003   | 47 | 10 | 1.19 (0.47-3.04) | 0.72 | 29 | 9  | 0.60 (0.21-1.70) | 0.34 |
| Pre-frail               | 2,343 | 40 | 1.63 (0.95-2.79) | 0.08    | 221 | 33 | 1 (Reference) |         | 128 | 38 | 0.81 (0.41-1.59) | 0.53 |
| Not frail               | 2,380 | 22 | 1 (Reference) |         | 142 | 20 | 1 (Reference) |         | 68 | 22 | 1 (Reference) |         |
| Short physical performance battery (SPPB) groups |   |     |             |         |   |     |             |         |   |     |             |         |
| Model 1 Low (0-6)       | 633 | 24 | 3.72 (2.03-6.82) | <0.0001 | 98 | 22 | 1.52 (0.75-3.09) | 0.25 | 79 | 20 | 0.50 (0.23-1.08) | 0.08 |
| Fair (7-9)              | 1,514 | 23 | 1.50 (0.85-2.64) | 0.17    | 132 | 19 | 0.95 (0.48-1.86) | 0.87 | 74 | 23 | 0.80 (0.40-1.63) | 0.54 |
| Good (10-12)            | 2,947 | 29 | 1 (Reference) |         | 189 | 25 | 1 (Reference) |         | 80 | 28 | 1 (Reference) |         |
| Model 2 Low (0-6)       | 633 | 24 | 3.23 (1.74-6.01) | 0.0002  | 98 | 22 | 2.00 (0.90-4.44) | 0.09 | 79 | 20 | 1 (Reference) |         |
| Fair (7-9)              | 1,514 | 23 | 1.37 (0.77-2.43) | 0.28    | 132 | 19 | 1.43 (0.68-2.99) | 0.35 | 74 | 23 | 1 (Reference) |         |
| Good (10-12)            | 2,947 | 29 | 1 (Reference) |         | 189 | 25 | 1 (Reference) |         | 80 | 28 | 1 (Reference) |         |

**Model 1**: Polytomous logistic regression adjusted for age, race-center, sex, and body mass index.

**Model 2**: Model 1 + additional adjustment for chronic obstructive pulmonary disease, diabetes, hypertensive medication, smoking status, systolic blood pressure, prevalent heart failure at visit 5 and prevalent peripheral artery disease at visit 5.

The odds ratios are comparing those with prevalent DVT to the comparison group within each physical function and quality of life outcome group.

OR: odds ratio; CI: confidence interval

* Prevalent DVT, CHD, and stroke events are mutually exclusive.

** Model failed to converge due to the small sample size and some covariates lacking individuals within their categories.
Table S9. Linear regression of prevalent venous thromboembolism (VTE) with physical function and quality of life outcomes, restricted to events that took place more than 2 years before the clinic visit date, Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013 and 2016 to 2017.

|                          | Prevalent VTE versus No Prevalent Events | Prevalent VTE versus Prevalent CHD* | Prevalent VTE versus Prevalent Stroke* |
|--------------------------|-----------------------------------------|-------------------------------------|----------------------------------------|
|                          | n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value | n | Coefficient (95% CI) | p-value |
| **Quality of life - mental score** |   |                          |    |   |                          |    |   |                          |    |
| Model 1                  |   | Prevalent VTE         | 148 | -0.09 (-1.32, 1.14) | 0.88 | 127 | -0.07 (-1.89, 1.75) | 0.94 | 137 | 0.04 (-2.05, 2.14) | 0.97 |
|                          |   | Comparison            | 5,295 | (Reference) |     | 335 | (Reference) |     | 157 | (Reference) |     |
| Model 2                  |   | Prevalent VTE         | 148 | 0.24 (-0.98, 1.47) | 0.70 | 127 | 0.36 (-1.66, 2.38) | 0.73 | 137 | 0.64 (-1.56, 2.84) | 0.57 |
|                          |   | Comparison            | 5,295 | (Reference) |     | 335 | (Reference) |     | 157 | (Reference) |     |
| **Quality of life - physical score** |   |                          |    |   |                          |    |   |                          |    |
| Model 1                  |   | Prevalent VTE         | 148 | -4.18 (-5.74, -2.63) | <0.0001 | 127 | 0.06 (-2.39, 2.51) | 0.96 | 137 | 1.55 (-1.04, 4.14) | 0.24 |
|                          |   | Comparison            | 5,295 | (Reference) |     | 335 | (Reference) |     | 157 | (Reference) |     |
| Model 2                  |   | Prevalent VTE         | 148 | -2.93 (-4.41, -1.45) | 0.0001 | 127 | -1.59 (-4.09, 0.90) | 0.21 | 137 | 1.10 (-1.53, 3.74) | 0.41 |
|                          |   | Comparison            | 5,295 | (Reference) |     | 335 | (Reference) |     | 157 | (Reference) |     |
| **Short physical performance battery (SPPB) score** |   |                          |    |   |                          |    |   |                          |    |
| Model 1                  |   | Prevalent VTE         | 136 | -1.44 (-1.81, -1.07) | <0.0001 | 120 | -0.54 (-1.17, 0.10) | 0.10 | 125 | 0.79 (0.02, 1.55) | 0.04 |
|                          |   | Comparison            | 5,018 | (Reference) |     | 306 | (Reference) |     | 142 | (Reference) |     |
| Model 2                  |   | Prevalent VTE         | 136 | -1.28 (-1.65, -0.92) | <0.0001 | 120 | -0.98 (-1.67, -0.30) | 0.01 | 125 | 0.75 (-0.07, 1.56) | 0.07 |
|                          |   | Comparison            | 5,018 | (Reference) |     | 306 | (Reference) |     | 142 | (Reference) |     |
| **Gait speed - 4m walk, m/s** |   |                          |    |   |                          |    |   |                          |    |
| Model 1                  |   | Prevalent VTE         | 130 | -0.07 (-0.11, -0.04) | <0.0001 | 114 | 0.01 (-0.04, 0.05) | 0.75 | 121 | 0.07 (0.02, 0.13) | 0.01 |
|                          |   | Comparison            | 4,981 | (Reference) |     | 301 | (Reference) |     | 139 | (Reference) |     |
| Model 2                  |   | Prevalent VTE         | 130 | -0.06 (-0.09, -0.03) | 0.0003 | 114 | -0.02 (-0.07, 0.04) | 0.56 | 121 | 0.08 (0.02, 0.13) | 0.01 |
|                          |   | Comparison            | 4,981 | (Reference) |     | 301 | (Reference) |     | 139 | (Reference) |     |
| **Gait speed - 4m walk (SPPB score 0-4)** |   |                          |    |   |                          |    |   |                          |    |
| Model 1                  |   | Prevalent VTE         | 135 | -0.38 (-0.49, -0.27) | <0.0001 | 119 | -0.12 (-0.32, 0.09) | 0.26 | 124 | 0.28 (0.03, 0.52) | 0.03 |
|                          |   | Comparison            | 4,988 | (Reference) |     | 305 | (Reference) |     | 142 | (Reference) |     |
| Model 2                  |   | Prevalent VTE         | 135 | -0.34 (-0.45, -0.23) | <0.0001 | 119 | -0.25 (-0.47, -0.03) | 0.03 | 124 | 0.25 (-0.01, 0.51) | 0.06 |
|                          |   | Comparison            | 4,988 | (Reference) |     | 305 | (Reference) |     | 142 | (Reference) |     |
| Endurance, feet† | Model 1 Prevalent VTE | 79 | -16.28 (-33.75, 1.19) | 0.07 | 71 | 17.04 (-8.18, 42.25) | 0.18 | 75 | 37.23 (10.16, 64.30) | 0.01 |
| Comparison | 2,528 (Reference) | 149 (Reference) | 73 (Reference) |
| Model 2 Prevalent VTE | 79 | -11.36 (-28.42, 5.71) | 0.19 | 71 | 15.37 (-12.02, 42.77) | 0.27 | 75 | 34.73 (6.24, 63.21) | 0.02 |
| Comparison | 2,528 (Reference) | 149 (Reference) | 73 (Reference) |

**Model 1**: Linear regression adjusted for age, race-center, sex, and body mass index.

**Model 2**: Model 1 + additional adjustment for chronic obstructive pulmonary disease, diabetes, hypertensive medication, smoking status, systolic blood pressure, prevalent heart failure, and prevalent peripheral artery disease.

The linear regression coefficient represents the difference between prevalent VTE and the comparison group of each physical function and quality of life outcome.

CI: confidence interval

* Prevalent VTE, CHD, and stroke events are mutually exclusive.

† From visit #6. The linear regression models include the same covariates from visit #6 except for chronic obstructive pulmonary disease, which is from visit #5.
Table S10. Multinomial logistic regression of prevalent venous thromboembolism (VTE) with physical function and quality of life outcomes, restricted to events that took place more than 2 years before the clinic visit date, Atherosclerosis Risk in Communities (ARIC) Study, 2011 to 2013.

| Frailty          | Model 1          | Model 2          |                      |
|------------------|------------------|------------------|----------------------|
|                  | Frail            | Pre-frail        | Not frail            |
| n                | VTE n            | OR (95% CI)      | p-value              |
| Frail            | 302              | 17               | 3.33 (1.79-6.17)     | 0.0001               |
| Pre-frail        | 2,381            | 78               | 2.06 (1.37-3.12)     | 0.001                |
| Not frail        | 2,393            | 35               | 1 (Reference)        |                      |
| Model 2          | Frail            | Pre-frail        | Not frail            |
| Frail            | 302              | 17               | 2.89 (1.54-5.43)     | 0.001                |
| Pre-frail        | 2,381            | 78               | 1.98 (1.30-3.00)     | 0.001                |
| Not frail        | 2,393            | 35               | 1 (Reference)        |                      |

| Short physical performance battery (SPPB) score | Model 1 |                   |                      |
|                                               | Low (0-6) | Fair (7-9) | Good (10-12) |
| n     | VTE n          | OR (95% CI) | p-value          | n    | VTE n       | OR (95% CI) | p-value | n     | VTE n       | OR (95% CI) | p-value |
| 657   | 48             | 4.06 (2.56-6.44) | <0.0001         | 108  | 42          | 1.47 (0.81-2.68) | 0.21    | 96    | 40          | 0.48 (0.25-0.92) | 0.03     |
| 1,530 | 39             | 1.48 (0.95-2.29) | 0.08            | 134  | 34          | 0.94 (0.54-1.64) | 0.82    | 81    | 38          | 0.75 (0.39-1.43) | 0.38     |
| 2,967 | 49             | 1 (Reference)   |                  | 184  | 44          | 1 (Reference)    |         | 90    | 47          | 1 (Reference)    |         |
| Model 2 | Low (0-6) |                   |                   |
| n     | VTE n          | OR (95% CI)      | p-value          | n     | VTE n       | OR (95% CI) | p-value | n    | VTE n       | OR (95% CI) | p-value |
| 657   | 48             | 3.50 (2.19-5.61) | <0.0001         | 108  | 42          | 2.17 (1.07-4.40) | 0.03    | 96    | 40          | 0.75 (0.39-1.43) | 0.38     |
| 1,530 | 39             | 1.37 (0.88-2.14) | 0.17            | 134  | 34          | 1.33 (0.71-2.49) | 0.37    | 81    | 38          | 2.06 (1.30-3.00) | 0.001    |
| 2,967 | 49             | 1 (Reference)   |                  | 184  | 44          | 1 (Reference)    |         | 90    | 47          | 1 (Reference)    |         |

**Model 1**: Multinomial logistic regression adjusted for age, race-center, sex, and body mass index.

**Model 2**: Model 1 + additional adjustment for chronic obstructive pulmonary disease, diabetes, hypertensive medication, smoking status, systolic blood pressure, prevalent heart failure at visit 5 and prevalent peripheral artery disease at visit 5.

The odds ratios are comparing those with prevalent VTE to the comparison group within each physical function and quality of life outcome group.

OR: odds ratio; CI: confidence interval

* Prevalent VTE, CHD, and stroke events are mutually exclusive.

** Model failed to converge due to the small sample size and some covariates lacking individuals within their categories.
Table S11. Visit 6 characteristics by prevalent disease status (venous thromboembolism [VTE], coronary heart disease [CHD], stroke, or no events), Atherosclerosis Risk in Communities (ARIC) Study, 2016 to 2017.

|                        | Prevalent VTE* | Prevalent CHD* | Prevalent Stroke* | No Prevalent Events |
|------------------------|----------------|----------------|-------------------|---------------------|
| n                      | 148            | 271            | 160               | 3,230               |
| Age, years             | 80.6 (5.0)     | 81.1 (5.0)     | 80.6 (4.8)        | 79.3 (4.7)          |
| Sex, %                 |                |                |                   |                     |
| Female                 | 62.8           | 39.5           | 46.9              | 60.8                |
| Male                   | 37.2           | 60.5           | 53.1              | 39.2                |
| Race, %                |                |                |                   |                     |
| White                  | 71.6           | 79.7           | 68.1              | 76.8                |
| African American       | 28.4           | 20.3           | 31.9              | 23.2                |
| Body mass index, kg/m² | 29.4 (6.5)     | 28.2 (5.0)     | 28.6 (5.3)        | 28.3 (5.4)          |
| Smoking status, %      |                |                |                   |                     |
| Current                | 2.7            | 10.0           | 8.8               | 6.9                 |
| Former                 | 39.9           | 50.6           | 53.1              | 45.4                |
| Never                  | 41.9           | 25.5           | 23.1              | 37.1                |
| Unknown                | 15.5           | 14.0           | 15.0              | 10.6                |
| Diabetes, %            | 36.5           | 39.9           | 46.9              | 31.0                |
| Hypertension medication, % | 83.8     | 94.1           | 91.3              | 75.3                |
| Prevalent chronic obstructive pulmonary disease, %‡ | 12.8 | 14.4 | 7.5 | 7.8 |
| Prevalent heart failure, % | 21.6     | 46.9           | 36.9              | 9.4                 |
| Prevalent peripheral artery disease, % | 12.2 | 14.0 | 15.6 | 7.4 |
| Systolic blood pressure, mmHg | 134.3 (20.1) | 135.1 (20.2) | 138.0 (19.6) | 135.0 (18.9) |
| Short physical performance battery (SPPB) groups † | 7.2 (3.3) | 8.0 (3.1) | 7.3 (3.1) | 8.8 (2.7) |
| Low (0-6)              | 31.8           | 24.0           | 31.3              | 16.6                |
| Fair (7-9)             | 29.7           | 27.7           | 26.9              | 29.1                |
| Good (10-12)           | 23.7           | 34.3           | 22.5              | 44.6                |
| Gait speed - 4m walk, m/s† | 0.86 (0.2) | 0.88 (0.2) | 0.83 (0.2) | 0.94 (0.2) |
| Gait speed - 4m walk (SPPB score 0-4)† | 3.2 (1.1) | 3.3 (1.0) | 3.2 (1.1) | 3.6 (0.8) |
| 0                      | 3.4            | 2.6            | 1.9               | 1.0                 |
| 1                      | 4.1            | 1.9            | 4.4               | 1.6                 |
| 2                      | 8.1            | 10.0           | 14.4              | 6.0                 |
| 3                      | 21.6           | 22.5           | 15.6              | 16.9                |
| 4                      | 45.3           | 46.9           | 41.9              | 62.8                |
| Endurance, feet† | 425.5 (90.1) | 424.5 (101.3) | 406.0 (94.7) | 455.3 (92.4) |

Data are presented as percent for categorical variables and as mean (standard deviation) for continuous variable.

* Prevalent VTE, CHD, and stroke events are not mutually exclusive.

† Sample size modestly smaller due to additional missing data.

‡ From visit #5.